Sota.Ns
SOTA.NS operates in the pharmaceuticals industry, focusing on drug development and commercialization, primarily generating revenue through product sales in the healthcare sector.
Business. SOTA.NS operates in the pharmaceuticals industry, focusing on drug development and commercialization, primarily generating revenue through product sales in the healthcare sector.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
SOTA.NS operates in the pharmaceuticals industry, focusing on drug development and commercialization, primarily generating revenue through product sales in the healthcare sector.
SOTA.NS has a debt-to-equity ratio of 0.82, indicating a moderate reliance on debt financing, and a current ratio of 1.35, suggesting it has sufficient short-term assets to cover its liabilities. However, the company's liquidity position is rated as medium, with negative net cash after subtracting total debt, signaling potential short-term liquidity constraints.
The company's profitability is reflected in a return on equity (ROE) of 15.07% and a return on assets (ROA) of 6.46%. These figures are in line with the industry's preferred metrics, but the operating cash flow of -43.31 million INR and free cash flow of -39.06 million INR indicate cash flow challenges that could affect long-term sustainability.
SOTA.NS's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This concentration increases exposure to market-specific risks and limits the company's ability to offset losses in one area with gains in another.
The company's growth trajectory is uncertain, with no specific revenue growth projections provided for the current or next fiscal year. Historical revenue data shows a total of 969.87 million INR, but without a clear growth rate or direction, it is difficult to assess future performance.
Risk factors include a medium liquidity risk due to negative net cash and a low dilution risk, as there is no indication of imminent share issuance. The company's capital structure and cash flow issues may necessitate future financing, which could lead to dilution if not managed carefully.
Recent events and filings have not been disclosed in the available data, so there is no information on recent strategic moves, product launches, or regulatory changes that could impact the company's performance.
- SOTA.NS has a moderate debt load and a current ratio of 1.35, indicating manageable short-term liquidity.
- The company's ROE of 15.07% and ROA of 6.46% suggest solid profitability, but negative operating and free cash flows raise concerns about sustainability.
- Revenue is concentrated in a single segment, increasing exposure to market-specific risks.
- Growth projections are unclear, and the company's financial health is contingent on improving cash flow and managing debt effectively.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- SOTA.NS Market data — financials · 2026-05-29